Dana-Farber Cancer Institute's D. Wenxin (Vincent) Xu shares research suggesting a blood test measuring levels of the KIM-1 biomarker could help assess the burden of disease in advanced kidney cancer and predict outcomes during first-line treatment.
Related Presenters
Medical Oncology
Dr. Xu received his MD from Harvard Medical School in 2014. He completed residency training in internal medicine at Beth Israel Deaconess Medical Center, followed by fellowship training in hematology and medical oncology also at Beth Israel ...
Related Videos
